This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed
by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in
the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.